The first clinical centre for the ASPro-PD trial opened in February of this year after reformulation of Ambroxol.
Evidence suggests that ambroxol increases the activity of the enzyme glucocerebrosidase, or GCase, which helps cells clear alpha-synuclein in brain cells.